Biodesix Reports Strong Q3 2024 Growth in Diagnostics
Company Announcements

Biodesix Reports Strong Q3 2024 Growth in Diagnostics

Biodesix, Inc. ( (BDSX) ) has released its Q3 earnings. Here is a breakdown of the information Biodesix, Inc. presented to its investors.

Biodesix, Inc. is a diagnostic solutions company specializing in blood-based tests for lung diseases, offering products such as the Nodify Lung® Nodule Risk Assessment and IQLung™ test portfolio, with a focus on improving patient outcomes in the healthcare sector.

Biodesix, Inc. announced its third-quarter 2024 financial results, highlighting a significant 35% increase in revenue over the same period last year, driven primarily by the growth in its lung diagnostic tests and maintaining a high gross profit margin.

A notable performance metric was the 40% year-over-year growth in lung diagnostics revenue, contributing to the overall $18.2 million in quarterly revenue. The company also reported a 77% gross profit margin, slightly up from 76.1% in the previous year, and an improvement in net loss by 6%. Despite a decrease in biopharmaceutical services revenue, Biodesix presented new clinical data and announced the CLARIFY study, indicating strategic efforts to enhance its diagnostic offerings.

Operating expenses rose by 29%, largely due to increased sales and marketing efforts to bolster product awareness and adoption. The company ended the quarter with $31.4 million in cash and equivalents, reflecting a decrease primarily due to final payments related to a past acquisition.

Looking ahead, Biodesix reiterates its revenue guidance for 2024 and anticipates achieving adjusted EBITDA profitability in the latter half of 2025, showcasing a continued commitment to financial growth and operational efficiency.

Related Articles
TheFlyMorning Movers: Apple dips, Amazon gains after earnings
TheFlyBiodesix files to sell 62.2M shares of common stock for holders
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App